Article citationsMore>>
Winstanley, C., Langille, M.G.I., Fothergill, J.L., Kukavica-Ibrulj, I., Paradis-Bleau, C., Sanschagrin, Fo., Thomson, N.R., Winsor, G.L., Quail, M.A. and Lennard, N. (2009) Newly Introduced Genomic Prophage Islands Are Critical Determinants of in Vivo Competitiveness in the Liverpool Epidemic Strain of Pseudomonas aeruginosa. Genome Research, 19, 12-23. http://dx.doi.org/10.1101/gr.086082.108
has been cited by the following article:
-
TITLE:
Common Preconditions for Safe Phage Therapy of Pseudomonas aeruginosa Infections
AUTHORS:
V. Krylov, E. Pleteneva, O. Shaburova, M. Bourkaltseva, S. Krylov, E. Chesnokova, O. Polygach
KEYWORDS:
Phage Therapy, Safety Measures, Pseudomonas aeruginosa
JOURNAL NAME:
Advances in Microbiology,
Vol.4 No.12,
September
16,
2014
ABSTRACT: One of the approaches to the treatment of
infections caused by multiply-(MDR) or extra drug- resistant (XDR) pathogenic
strains may be application of bacterial viruses (bacteriophages)— phage
therapy. Results of a long, but quite limited use of phage therapy in several
Eastern European countries, as well as experiments on animal models in Western
countries support the possibility to use phage therapy. However, given the role
of phages in the evolution of bacterial pathogens, it is necessary to discuss
and evaluate negative consequences of mass introduction of phage therapy, as
the measures necessary for its safe use. We discuss some actions in case of
transiting to world-wide use of phage therapy with purpose to prolong the
active life of phage therapy and to diminish possible complications.